artherosclerosis and lipid metabolism in IHD Flashcards

(38 cards)

1
Q

function of trigs

A

energy storage and production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

function of choolesterol

A
  • steroid synthesis
  • bile acids
  • cell membrane
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

first decade

A

foam cells > fatty streaks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

third decade

A

intermediate lesion > atheroma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

fourth decade

A

fibrous plaque (fibro atheroma) > rupture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

athero is a product of

A

lifestyle, and then aggravated by genetic factors… NB bc this statement is not reversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

more atherogenic LDL

A

small dense LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

FHyperC

A
  • requires intervention from a young age
  • single gene defect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

leading risk factr that predicts MI

A

LDL/HDL leves

  • smoking is a close second, so pick only when LDL isnt listed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

commonest cause of athero world wide

A

metabolic syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

two extremes of athero in SA

A
  • SA black population > socioeconomic status, high prevalance of underlying conditions
  • familial hyperC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

how do we check LDL levels

A

lipogram

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

comparisons of athero across populations

A
  • hugher in SA jews, asiabs and afrikaneers and could be due to lifestyle, genes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

is FH rare

A

no, its not a rare genetic disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

diagnosis for FH

A

anything more than 5 mmol/L with a family history = should be concerned

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

3 ways to spot hypercholesteraemia

A
  • arcus seniles
  • xanthelesma
    -thickened tendons
10
Q

whats the target LDL levels for high risk patient

11
Q

specific statin indicated to lower LDL

A

simvastatin = low intensity, affordable

11
Q

rule of 6

A

with each doubling of statin dose, there is 6% reduction in cholesterol

12
Q

drug inhibitng choesterol absorption

13
Q

ezetimibe - 3

A
  • inhibits Niemann Pick C1 like-1 protein
  • located in the epithelial brush border
  • 20% reduction
14
Q

residual lipoprotein risk

A

patient diagnosed late, might not get good reply

14
Q

therapies for severe HC

A
  • pcsk9 inhibitors
  • mAbs
  • siRNA
  • ANGPTL3 inhibitors
15
Q

FIRST LINE THERAP Y FOR HYPERCHOLE..

A

statins + ezetimibe

  • but they are not effective in patients with established ASCVD
16
MOA of PCSK9 inhibitors
increase LDL receptor availability on liver cells, allowing more LDL cholesterol to be cleared from the blood.
16
when are PCSK9 inhibitors given - 4
- severe heterozygous FH and non FH who havent responded well to statin+ ezetimibe - also for homozygouse pt - progressive CAD - statin intolerance
17
is FH well diagnosed
no, a lot of people with FH dont even know athey do, so less controlled
18
inclisiran
gene silencing by stopping the production of PCSK9 by hepatocytes (turning off the tap)
18
advantages of inclisiran
- harness the natural process of RNAi - nucleotides are modified for durability and low immunogenecity - distributed to liver due to GaINaC conjugation
19
remnant cholesterol
is the leftover cholesterol in VLDL and IDL after fat is removed — and it can clog arteries like LDL. DISCLAIMER : all other types can clog arteries as well
19
ANGPTL3
- plays a central role in lipoprotein metabolism -it is a circulating protein synthesized in the liver having pleitropic functions that inhibits intravascular LPL and endothelial lipase
20
ANGPTL3 inhibitor
- homozygous FH - reduces the risk of ASCVD
20
what can ANGPTL3 be combined withstatins and PCSK9 inhibitors
21
normal total cholestrol
3 mmol/l
21
concept I for strategies to reduce ASCVD
start early
21
administration of LDL - lowering therapies
- oral (common ones) - daily - mAbs - monthly/ bi-monthly - ASO (orsen) - weekly/ monthly - siRNA - bi annually - vaccination - yearly - gene editing - clear for life ig
22
concept II
treat much more aggresively
22
concept III
use combination therapy